Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer
Technology in Cancer Research & Treatment · 2026-05 · 25
DOI: 10.1177/15330338261452636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 19.05.2026. Verfasst von Chaopeng Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Guangdong Nongken Central School of Clinical Medicine, Guangdong Medical University (Central Hospital of Guangdong Provincia…. Hauptthemen laut MEDLINE: Transcription Factors, Carcinoma, Non-Small-Cell Lung, Nuclear Proteins, DNA Helicases. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
SMARCA4-deficient NSCLC is an aggressive subtype lacking robust biomarkers and therapeutic targets. To define the expression pattern and clinical significance of DPP4 in SMARCA4-dNSCLC and explore whether DPP4 may represent a therapeutic vulnerability in this subtype. Materials and Methods The Cancer Genome Atlas NSCLC cohort was analyzed to compare SMARCA4 -low tumors with adjacent normal lung using differential expression, Cox regression, protein–protein interaction networks, and machine-learning ranking. An exploratory immunohistochemistry case series of SMARCA4-dNSCLC from three centers (n=9) quantified DPP4 by percentage of tumor cells; ≥20% cells defined DPP4-high. Clinicopathologic features, RECIST response, and survival were summarized descriptively by DPP4 status. In HCC827 cells, SMARCA4 knockdown and DPP4 inhibition (P32/98) were evaluated alone and in combination using colony-formation, and motility (migration/wound-healing) assays.
Results
DPP4 was downregulated in SMARCA4 -low tumors versus adjacent normal lung, yet within tumors higher residual DPP4 expression was associated with worse overall and disease-free survival. In the immunohistochemistry case series, DPP4 protein expression was weaker in SMARCA4-dNSCLC than in adjacent alveolar epithelium. Within this low-expressing background, DPP4-high tumors showed descriptive trends toward inferior survival, lower disease-control rate after first-line therapy, and more extensive baseline organ involvement than DPP4-low tumors. In vitro, SMARCA4 knockdown and P32/98 each reduced clonogenic growth and motility versus control, with the combination producing the greatest inhibition (about 60%–70% reductions).
Conclusions
DPP4 is downregulated at the mRNA and protein levels in SMARCA4-dNSCLC compared with normal lung, yet higher residual expression may mark a more aggressive phenotype. Combined SMARCA4 knockdown and DPP4 inhibition suppress growth and motility in vitro, suggesting DPP4 as a candidate prognostic marker and a candidate therapeutic target that requires orthogonal specificity controls and validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Guangdong Nongken Central School of Clinical Medicine, Guangdong Medical University (Central Hospital of Guangdong Provincial Nongken), Zhanjiang, Guangdong, China.
- Department of Pathology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
- Department of Imaging, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China.
- Department of Pathology, Guangdong Medical University (Central People's Hospital of Zhanjiang), Zhanjiang, Guangdong, China.
- Department of Organ Transplantation, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Di…
- Department of Thoracic Surgery, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China.
ORCID-Profile: Zhibin Xu
Zitieren
APA
Chen, C., Zhong, Z., Luo, X., Dai, W., Xu, L., Cai, W., Xu, Z., Liang, G., & Pang, L. (2026). Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261452636
Vancouver
Chen C, Zhong Z, Luo X, Dai W, Xu L, Cai W, et al. Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261452636
BibTeX
@article{Chen2026,
author = {Chen, Chaopeng and Zhong, Zebin and Luo, Xiaoling and Dai, Weiping and Xu, Lujian and Cai, Wenping and Xu, Zhibin and Liang, Guolian and Pang, Lijuan},
title = {Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261452636}
}
EUVIMED